Halozyme Therapeutics Inc - ESG Rating & Company Profile powered by AI
This ESG score covers 17 UN SDGs including: 'Quality Education', 'Climate Action' and 'Partnerships for the Goals'. Complete Sustainability assessment of Halozyme Therapeutics Inc can be accessed by signing up for free. Jump to the end of this page for potential risks for Halozyme Therapeutics Inc based on sector, location and marketcap.
Halozyme Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.5; made up of an environmental score of 1.3, social score of 3.4 and governance score of 2.7.
2.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1481 | Tissue Regenix Group PLC | 2.6 | Medium |
| 1481 | Twist Bioscience Corp | 2.6 | Medium |
| 1499 | Halozyme Therapeutics Inc | 2.5 | Medium |
| 1499 | Akeso Inc | 2.5 | Medium |
| 1499 | Allergan plc | 2.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Halozyme Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Halozyme Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Halozyme Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Halozyme Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Halozyme Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Halozyme Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Halozyme Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Halozyme Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Halozyme Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Halozyme Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Halozyme Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Halozyme Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Halozyme Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Halozyme Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Halozyme Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Halozyme Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Halozyme Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Halozyme Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.